Literature DB >> 16846798

Screening the receptorome: an efficient approach for drug discovery and target validation.

Ryan T Strachan1, Gina Ferrara, Bryan L Roth.   

Abstract

The receptorome, comprising at least 5% of the human genome, encodes receptors that mediate the physiological, pathological and therapeutic responses to a vast number of exogenous and endogenous ligands. Not surprisingly, the majority of approved medications target members of the receptorome. Several in silico and physical screening approaches have been devised to mine the receptorome efficiently for the discovery and validation of molecular targets for therapeutic drug discovery. Receptorome screening has also been used to discover, and thereby avoid, the molecular targets responsible for serious and unforeseen drug side effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16846798     DOI: 10.1016/j.drudis.2006.06.012

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  22 in total

Review 1.  Ensemble of G protein-coupled receptor active states.

Authors:  P S-H Park
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.

Authors:  Sean Ekins; Nadia K Litterman; Christopher A Lipinski; Barry A Bunin
Journal:  Pharm Res       Date:  2015-08-27       Impact factor: 4.200

3.  Mastering tricyclic ring systems for desirable functional cannabinoid activity.

Authors:  Ravil R Petrov; Lindsay Knight; Shao-Rui Chen; Jim Wager-Miller; Steven W McDaniel; Fanny Diaz; Francis Barth; Hui-Lin Pan; Ken Mackie; Claudio N Cavasotto; Philippe Diaz
Journal:  Eur J Med Chem       Date:  2013-09-29       Impact factor: 6.514

Review 4.  Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.

Authors:  Bryan L Roth; Wesley K Kroeze
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

5.  Drug repurposing: far beyond new targets for old drugs.

Authors:  T I Oprea; J Mestres
Journal:  AAPS J       Date:  2012-07-24       Impact factor: 4.009

Review 6.  Mitigating risk in academic preclinical drug discovery.

Authors:  Jayme L Dahlin; James Inglese; Michael A Walters
Journal:  Nat Rev Drug Discov       Date:  2015-04       Impact factor: 84.694

7.  Cross-pharmacology analysis of G protein-coupled receptors.

Authors:  Ferran Briansó; Maria C Carrascosa; Tudor I Oprea; Jordi Mestres
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

8.  LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor.

Authors:  Peter B Hedlund; Marcello Leopoldo; Silvio Caccia; Gor Sarkisyan; Claudia Fracasso; Giuliana Martelli; Enza Lacivita; Francesco Berardi; Roberto Perrone
Journal:  Neurosci Lett       Date:  2010-06-23       Impact factor: 3.046

9.  Differences between high- and low-affinity complexes of enzymes and nonenzymes.

Authors:  Heather A Carlson; Richard D Smith; Nickolay A Khazanov; Paul D Kirchhoff; James B Dunbar; Mark L Benson
Journal:  J Med Chem       Date:  2008-10-01       Impact factor: 7.446

10.  Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors.

Authors:  Charles D Nichols; Bryan L Roth
Journal:  Front Mol Neurosci       Date:  2009-10-23       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.